HansPeter Rudolf - Shield Therapeutics Chief Officer
| SHIEF Stock | USD 0.15 0.02 15.38% |
Insider
HansPeter Rudolf is Chief Officer of Shield Therapeutics plc
| Phone | 44 1915 118 500 |
| Web | https://www.shieldtherapeutics.com |
Shield Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3405) % which means that it has lost $0.3405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5703) %, meaning that it generated substantial loss on money invested by shareholders. Shield Therapeutics' management efficiency ratios could be used to measure how well Shield Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| JD BA | HLS Therapeutics | 42 | |
| Cecilia Coupland | Orexo AB | 47 | |
| David Abitbol | Cannara Biotech | N/A | |
| Gilbert Godin | HLS Therapeutics | 64 | |
| Julia Bouvet | Cannara Biotech | N/A | |
| Wai FCS | Kintor Pharmaceutical Limited | 68 | |
| Ian Farrell | Jushi Holdings | N/A | |
| Brian Sherman | Cannara Biotech | N/A | |
| Michael Perlman | Jushi Holdings | N/A | |
| Fredrik Jarrsten | Orexo AB | 56 | |
| James Cabral | Jushi Holdings | N/A | |
| Ma Liandong | Kintor Pharmaceutical Limited | 64 | |
| Trenton Woloveck | Jushi Holdings | 38 | |
| Adam August | Grown Rogue International | 45 | |
| Obie Strickler | Grown Rogue International | 40 | |
| Neelu Atwal | Biosyent | N/A | |
| Dennis Urbaniak | Orexo AB | 54 | |
| Anthony Manouk | Cannara Biotech | N/A | |
| Sanjiv Sharma | HLS Therapeutics | 67 | |
| Tobi Lebowitz | Jushi Holdings | N/A | |
| Youzhi Tong | Kintor Pharmaceutical Limited | 60 | |
Management Performance
| Return On Equity | -0.57 | |||
| Return On Asset | -0.34 |
Shield Therapeutics plc Leadership Team
Elected by the shareholders, the Shield Therapeutics' board of directors comprises two types of representatives: Shield Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shield. The board's role is to monitor Shield Therapeutics' management team and ensure that shareholders' interests are well served. Shield Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shield Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Suzanne Wood, Group Director | ||
| Christian MD, CoFounder Director | ||
| Carol Akinola, Head Information | ||
| HansPeter Rudolf, Chief Officer | ||
| Lucy HuntingtonBailey, G Sec | ||
| Jos MD, Chief Officer | ||
| Gregory Madison, CEO Director |
Shield Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Shield Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.34 | |||
| Operating Margin | (7.83) % | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 585.67 M | |||
| Shares Owned By Insiders | 42.23 % | |||
| Shares Owned By Institutions | 13.58 % | |||
| Price To Book | 0.75 X | |||
| Price To Sales | 7.37 X | |||
| Revenue | 1.52 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Shield OTC Stock
Shield Therapeutics financial ratios help investors to determine whether Shield OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shield with respect to the benefits of owning Shield Therapeutics security.